Stockreport

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics, Inc.  (SNSE) 
PDF - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial d [Read more]